HC Wainwright Issues Positive Forecast for Insmed Earnings

Insmed, Inc. (NASDAQ:INSM) – Analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Insmed in a note issued to investors on Thursday, March 26th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of ($1.00) per share for the quarter, up from their previous estimate of ($1.05). HC Wainwright has a “Buy” rating and a $245.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.58) EPS, FY2027 earnings at $0.22 EPS, FY2028 earnings at $2.40 EPS, FY2029 earnings at $6.01 EPS and FY2030 earnings at $10.09 EPS.

Several other research analysts have also weighed in on the stock. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Truist Financial set a $205.00 target price on shares of Insmed in a report on Monday, January 12th. Guggenheim dropped their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $166.00 to $212.00 in a report on Monday. Finally, Jefferies Financial Group initiated coverage on shares of Insmed in a research note on Monday, March 16th. They set a “buy” rating and a $228.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insmed presently has an average rating of “Buy” and an average target price of $212.38.

Insmed Stock Up 6.7%

Shares of NASDAQ:INSM opened at $163.52 on Monday. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The firm has a market cap of $35.25 billion, a price-to-earnings ratio of -25.51 and a beta of 1.13. The stock’s 50-day moving average price is $149.97 and its two-hundred day moving average price is $166.42. Insmed has a 12-month low of $60.40 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. During the same period in the prior year, the firm earned ($1.32) EPS. Insmed’s revenue for the quarter was up 152.6% on a year-over-year basis.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently modified their holdings of INSM. CoreCap Advisors LLC acquired a new position in Insmed during the 4th quarter worth approximately $27,000. Reflection Asset Management acquired a new stake in Insmed in the fourth quarter valued at approximately $30,000. GraniteShares Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter valued at approximately $30,000. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in shares of Insmed during the fourth quarter worth $32,000.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48. Following the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,226,071.20. This trade represents a 3.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 748 shares of Insmed stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total transaction of $116,942.32. Following the transaction, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. The trade was a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 189,651 shares of company stock worth $31,533,654 over the last three months. 3.00% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.